The Research Arm as a Structural Moat
An integrated clinical research division is a structural moat because it generates evidence the platform owns, retains physicians who want to do science alongside their clinical work, and creates a regulatory and IRB infrastructure competitors would need years to build. Most multi-specialty platforms cannot replicate it because their physician base is not research-engaged.
A clinical research division is a structurally awkward thing to add to a healthcare platform after the fact. It requires IRB infrastructure, regulatory expertise, sponsor relationships, and — most critically — a physician base that is research-engaged enough to be principal investigators and sub-investigators on real protocols. Platforms that did not start with that physician profile cannot synthesize it later.
ZMD Group's bet is that starting with a physician-engaged base, anchoring the research division in Boston, and integrating research output directly into the family of brands creates a moat that compounds over time. Patients benefit from earlier access to evidence-supported interventions; physicians retain the part of medicine that brought many of them into the field; and the platform develops a body of proprietary outcomes data that is not available to non-research-integrated competitors.
Written for ZMD Group Editorial. Inquiries: [email protected].